Advances in genetics and genomics are transforming medical practice, resulting in a dramatic growth of genetic testing in the health care system. The rapid development of new technologies, however, has also brought challenges, including the need for rigorous evaluation of the validity and utility of genetic tests, questions regarding the best ways to incorporate them into medical practice, and how to weigh their cost against potential short- and long-term benefits. As the availability of genetic tests increases so do concerns about the achievement of meaningful improvements in clinical outcomes, costs of testing, and the potential for accentuating medical care inequality. Given the rapid pace in the development of genetic tests and new testing technologies, An Evidence Framework for Genetic Testing seeks to advance the development of an adequate evidence base for genetic tests to improve patient care and treatment. Additionally, this report recommends a framework for decision-making regarding the use of genetic tests in clinical care.
Copyright 2017 by the National Academy of Sciences. All rights reserved.
American Society of Clinical Oncology Policy Statement Update: Genetic Testing for Cancer SusceptibilityAmerican Society of Clinical Oncology. J Clin Oncol 21 (12), 2397-406. PMID 12692171.As the leading organization representing cancer specialists involved in patient care and clinical research, the American Society of Clinical Oncology (ASCO) reaffirms its …
Genomic Analysis in the Clinic: Benefits and Challenges for Health Care Professionals and Patients in BrazilP Ashton-Prolla et al. J Community Genet 6 (3), 275-83. PMID 26040235.Despite significant advances in the diagnosis and treatment of genetic diseases in the last two decades, there is still a significant proportion where a causative mutatio …
Recommendations From the EGAPP Working Group: Does Genomic Profiling to Assess Type 2 Diabetes Risk Improve Health Outcomes?Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group et al. Genet Med 15 (8), 612-7. PMID 23492873.Prevention of type 2 diabetes is a public health priority. Improvements in the outcomes associated with genomic profiling could have important impacts. Traditional risk f …
Recommendations From the EGAPP Working Group: Genomic Profiling to Assess Cardiovascular Risk to Improve Cardiovascular HealthEvaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Genet Med 12 (12), 839-43. PMID 21042222.Prevention of CVD is a public health priority. Improvements in outcomes associated with genomic profiling could have important impacts. Traditional risk factors such as t …
American Medical Society for Sports Medicine Position Statement: Concussion in SportKG Harmon et al. Br J Sports Med 47 (1), 15-26. PMID 23243113. - Review▸ Additional research is needed to validate current assessment tools, delineate the role of NP testing and improve identification of those at risk of prolonged post-concu …